Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: A case report

He,Shizhi; Li,Pingdong; Chen,Xiaohong; Yu,Zhenkun

doi:10.3892/ol.2013.1364

Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: A case report

Authors:
- Shizhi He
- Pingdong Li
- Xiaohong Chen
- Zhenkun Yu
View Affiliations

Affiliations: Department of Otolaryngology‑Head and Neck Surgery, Beijing Tongren Hospital, Key Laboratory of Otolaryngology‑Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing 100730, P.R. China
Published online on: May 24, 2013 https://doi.org/10.3892/ol.2013.1364
Pages: 448-452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastases to the supraclavicular region usually originate from the head and neck or from infraclavicular tumors. Ovarian primaries of supraclavicular metastases are extremely rare. The present study reports the case of a 60‑year‑old patient with a bilateral supraclavicular mass that was diagnosed as a poorly‑differentiated squamous cell carcinoma of unknown primary, following a fine‑needle aspiration biopsy (FNAB) and comprehensive clinical investigation. The analysis of a peripheral blood sample using the CellSearch system revealed the presence of circulating tumor cells (CTCs) that were positive for epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK) expression. Since EpCAM is usually expressed in adenocarcinoma, an excisional biopsy of the right supraclavicular lymph node was performed. The patient was diagnosed with occult ovarian low‑grade serous carcinoma by immunohistochemistry. To the best of our knowledge, this is the first report to demonstrate that CTCs may be detected in the peripheral blood of a patient with cancer of unknown primary (CUP) by using the CellSearch system. A literature review was performed to analyze the diagnostic procedures of CUP metastatic to the cervical lymph nodes and the clinical features of CTCs.

View Figures

View References

1.	Strojan P, Ferlito A, Medina JE, et al: Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck. 35:123–132. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Gervasoni A, Sandri MT, Nascimbeni R, et al: Comparison of three distinct methods for the detection of circulating tumor cells in colorectal cancer patients. Oncol Rep. 25:1669–1703. 2011.PubMed/NCBI
3.	Strojan P, Ferlito A, Langendijk JA, et al: Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck. 35:286–293. 2013. View Article : Google Scholar : PubMed/NCBI
4.	Haas I, Hoffmann TK, Engers R and Ganzer U: Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol. 259:325–333. 2002.PubMed/NCBI
5.	Giridharan W, Hughes J, Fenton JE and Jones AS: Lymph node metastases in the lower neck. Clin Otolaryngol Allied Sci. 28:221–226. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Chepeha D, Koch W and Pitman K: Management of unknown primary tumor. Head Neck. 25:499–504. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Cerezo L, Raboso E and Ballesteros AI: Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol. 13:88–97. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Oien KA: Pathologic evaluation of unknown primary cancer. Semin Oncol. 36:8–37. 2009. View Article : Google Scholar : PubMed/NCBI
9.	van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW and den Toonder JM: Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res. 71:5955–5960. 2011.PubMed/NCBI
10.	Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Smirnov DA, Foulk BW, Doyle GV, Connelly MC, Terstappen LW and O’Hara SM: Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Research. 66:2918–2922. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Marrinucci D, Bethel K, Bruce RH, et al: Case study of the morphologic variation of circulating tumor cells. Human Pathol. 38:514–519. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Bellone S, Siegel ER, Cocco E, et al: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 19:860–866. 2009. View Article : Google Scholar
14.	Shim HS, Yoon BS and Cho NH: Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Human Pathol. 40:693–698. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Miller MC, Doyle GV and Terstappen LW: Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010:6174212010. View Article : Google Scholar : PubMed/NCBI
16.	Poveda A, Kaye SB, McCormack R, et al: Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 122:567–572. 2011. View Article : Google Scholar
17.	Rusthoven KE, Koshy M and Paulino AC: The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 101:2641–2649. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Kwee TC and Kwee RM: Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 19:731–744. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K and Schwaiger M: Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009:2087252009. View Article : Google Scholar : PubMed/NCBI
20.	Fanti S, Nanni C, Castellucci P, et al: Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding. Cancer Imaging. 6:20–23. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Dvoretsky PM, Richards KA, Angel C, et al: Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol. 19:57–63. 1988. View Article : Google Scholar : PubMed/NCBI
22.	Euscher ED, Silva EG, Deavers MT, Elishaev E, Gershenson DM and Malpica A: Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol. 28:1217–1223. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Moll R, Löwe A, Laufer J and Franke WW: Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 140:427–447. 1992.PubMed/NCBI
24.	Rubin BP, Skarin AT, Pisick E, Rizk M and Salgia R: Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 10:77–82. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Roh MS and Hong SH: Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. J Korean Med Sci. 17:512–517. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P and Dietel M: Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 29:233–240. 1996. View Article : Google Scholar
27.	Mittal K, Soslow R and McCluggage WG: Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 132:402–423. 2008.PubMed/NCBI
28.	Acs G, Pasha T and Zhang PJ: WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 23:110–118. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Malpica A, Deavers MT, Gershenson D, Tortolero-Luna G and Silva EG: Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential. Am J Surg Pathol. 25:988–996. 2001. View Article : Google Scholar
30.	Verbruggen MB, Verheijen RH, van de Goot FR, van Beurden M, Dorsman JC and van Diest PJ: Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases. Am J Surg Pathol. 30:739–743. 2006. View Article : Google Scholar : PubMed/NCBI